title: Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
abstract: OBJECTIVE
  To determine (a) the proportion of patients at high risk of cardiovascular events who achieve low-density lipoprotein cholesterol (LDL-C) goals as recommended by the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) guidelines, and (b) the predictors of poor LDL-C control.
  
  
  METHODS
  Two open-label, prospective, non-randomised, observational studies (study 1 with n=19 194 patients, predominantly with coronary artery disease (CHD); study 2 with n=19 484 patients, pre-dominantly with diabetes mellitus (DM)). Patients received, usually after statin pretreatment, ezetimibe 10 mg plus simvastatin as fixed-dose combinations over 3 months. Bivariate and multivariate regression analysis was performed to identify factors associated with poor LDL-C control.
  
  
  RESULTS
  At study end, 38% (up from 4.7% at baseline) of CHD and 35% (up from 3.3% at baseline) of diabetic patients achieved the target LDL value <100 mg/dl (2.6 mmol/l) after treatment with a fixed-dose ezetimibe-simvastatin combination. In both studies, concomitant atherosclerotic disease was associated with good control. Conversely, factors associated with poor control were, among others, high baseline LDL-C values, pretreatment with certain statins, and (in the DM study) high HbA(1c), and high body mass index.
  
  
  CONCLUSIONS
  Under real world, general practice conditions, a substantial proportion of high-risk patients with CHD and/or DM met LDL-C target levels on dual cholesterol inhibition with ezetimibe/simvastatin. A limited number of easily recognisable factors allow physicians to identify high risk patients whose LDL-C is likely to be difficult to control. Early identification of this patient group may have profound clinical benefits in general practice by enabling specific early interventions such as counselling on physical activity, dietary support and/or follow up visits to the GP.
authors.affiliation: Medical Department, essex Pharma, Munich, Germany. steven.hildemann@essex.de
authors.forename: Steven
authors.initials: S
authors.lastname: Hildemann
authors.forename: Barbara
authors.initials: B
authors.lastname: Karmann
authors.forename: David
authors.initials: D
authors.lastname: Pittrow
authors.forename: Christian
authors.initials: C
authors.lastname: Barho
authors.forename: Harald
authors.initials: H
authors.lastname: Darius
authors.forename: Christoph
authors.initials: C
authors.lastname: Bode
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases; D008078:Cholesterol, LDL / Q000097:blood; D003920:Diabetes Mellitus; D000069438:Ezetimibe; D005260:Female; D005544:Forecasting; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D011446:Prospective Studies; D018570:Risk Assessment; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019821:Simvastatin; D000069438:Ezetimibe